Genric Name: Ziprasidone HCL
PRAZIP (Shrooq)
SYCOZIP (Akhai)
XEPEX (Genetics Pharma)
XEPEX (Danas)
ZIPADONE (Mediate)
ZAPRIS (Enlgish)
ZELDOX (Pfizer Pakistan)
ZIDONE (Paramount)
ZEPRIS (Panacea)
ZIPRAMAX (Shrooq)
ZIPRAS (Wellborne)
ZIPEX (Genome)
ZIPSYDE (Genome)
ZIPRA (CCL)
ZIRADON (Neutro Pharma)
ZIPRAWIN (Amarant)
ZIPRONIA (Ipram Pharma)
Indications:
Management of schizophrenia and other psychotic disorders,
and for maintenance of clinical improvement
and prevention of relapse during continuation therapy
Dose:
By Mouth
Adults: 40 mg twice daily, to be taken with food. Daily
dosage may subsequently be adjusted on the basis of individuals' clinical status
up to a maximum of 80 mg twice daily. If indicated, the maximum recommended
dose may be reached as early as Day 3 treatment.
By Intramuscularism
IM: 10 mg q2hr or 20 mg q4hr, not to exceed 40 mg/day, use
IM for up to 3 days, and switch to PO if continuing past this time.
Contraindications:
Known hypersensitivity to ziprasidone or any of the
excipients, known QT interval prolongation including congenital long QT
Syndrome, Recent myocardial infarction
Uncompensated heart failure: Cardiac arrhythmias requiring
treatment with Class IA and III antiarrhythmics drugs.
Children: Safety and effectiveness in children under 18
years have not been established.
Elderly: Generally, no dosage adjustment is required in
elderly patients (65 years and over)
Renal impairment: No dosage adjustment is required in
patients with renal impairment
Hepatic impairment: In patients with mild to moderate
hepatic insufficiency, lower doses should be considered. There is a lack of
experience in patients with severe hepatic insufficiency and ziprasidone should
be used with caution in this group
Use in Smokers: No dosage adjustment is required in patients
who smoke.
Side effects/adverse reactions:
The following adverse reactions have been reported during
post-marketing experience.
Cardiovascular: Postural hypotension
Heart rate/Rhythm: tachycardia
Psychiatric: Insomnia
Skin and Appendage: rash
Interactions
Drugs:
Carbamazepine: Possibly decreased blood ziprasidone level
CNS depressants: Increased CNS Depression
Dopamine agonists, levodopa: Decreaed therapecutic effects of these drugs that prolong QT interval ( including quinidine, dofetilide, pimozide, sotalol, thioridazine, and sparfloxacin ): increased risk of prolonges QT or QTc interval)
Ketoconazole : possibly increased blood ziprasidone level
